General Biologicals (ROCO:4117) ROCE %: 33.61% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4117 General Biologicals Corp ROCO:4117
50 GF Score
Price NT$10.40
GF Value NT$14.06
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is General Biologicals ROCE %?

General Biologicals ROCO:4117 -9.96% 50 ROCE % is 33.61% as of Dec. 2025. GuruFocus rates ROCO:4117 with a GF Score™ of 50/100 and a GF Value™ of NT$14.06 (Modestly Undervalued). The stock has 8 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. General Biologicals's annualized ROCE % for the quarter that ended in Dec. 2025 was 33.61%.

General Biologicals  (ROCO:4117) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

General Biologicals ROCE % Related Terms

General Biologicals ROCE % Historical Data

* Premium members only.

The historical data trend for General Biologicals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

General Biologicals ROCE % Chart

General Biologicals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.13 -2.22 -11.87 -9.11 13.92

General Biologicals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.89 -9.33 -7.51 -7.66 33.61
ROCO:4117
50GF Score
General Biologicals Corp ROCO:4117
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

General Biologicals ROCE % Calculation

General Biologicals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=525.233/( ( (3479.288 - 405.595) + (4869.512 - 396.995) )/ 2 )
=525.233/( (3073.693+4472.517)/ 2 )
=525.233/3773.105
=13.92 %

General Biologicals's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=1290.978/( ( (3539.876 - 330.237) + (4869.512 - 396.995) )/ 2 )
=1290.978/( ( 3209.639 + 4472.517 )/ 2 )
=1290.978/3841.078
=33.61 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 33.61% mean?
General Biologicals (ROCO:4117) has a ROCE % of 33.61% as of Dec. 2025.
Is General Biologicals' ROCE % too high?
General Biologicals' current ROCE % is 33.61%. The Drug Manufacturers industry median ROCE % is 7.06. General Biologicals' value of 33.61% is 376.1% above this industry median. Overall, General Biologicals has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does General Biologicals' ROCE % compare to ZTS and UTHR?
General Biologicals' ROCE % of 33.61% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.06. General Biologicals' value of 33.61% is 376.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.06, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. General Biologicals's current ROCE % of 33.61% is 376.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. General Biologicals's current ROCE % is 33.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is General Biologicals stock overvalued right now?
Based on GuruFocus' analysis, General Biologicals (ROCO:4117) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$14.06, compared to a current price of NT$10.40 — trading 26% below its estimated fair value. The current ROCE % is 33.61% and 376.1% above the Drug Manufacturers industry median of 7.06. General Biologicals' overall GF Score™ is 50/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For General Biologicals (ROCO:4117), the current ROCE % is 33.61% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is General Biologicals (ROCO:4117) Overvalued in 2026?

Based on GuruFocus' analysis, General Biologicals stock appears to be undervalued. The current stock price of NT$10.40 is trading 26% below its estimated GF Value™ of NT$14.06. GuruFocus considers General Biologicals to be Modestly Undervalued.

Key valuation signals for ROCO:4117:

  • ROCE %: 33.61%
  • GF Value™: NT$14.06 vs. price of NT$10.40 (26% below fair value)
  • GF Score™: 50/100 with 8 warning signs
  • Industry Position: 376.1% above the Drug Manufacturers median

No single metric tells the full story. See the ROCO:4117 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

General Biologicals Business Description

Address No-6, Innovation First Road, Hsinchu Science Park, Hsinchu, TWN, 300092
General Biologicals Corp is a developer and manufacturer of vitro diagnostic devices in Taiwan. It offers research development, marketing and servicing of products and solutions for hospitals, medical laboratories, blood banks, and research and industry. Its products include Anti-HDV, HIV Ag-Ab COMB, Anti-HBs, and many others.
50GF Score

Get the complete analysis for ROCO:4117

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$10.40
Price
NT$14.06
GF Value